Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
BRCA1
BRCA2
Breast cancer
Chemoprevention
Raloxifene
Tamoxifen
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
15
11
2022
accepted:
24
05
2023
medline:
24
7
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
Chemoprevention with a selective estrogen receptor modulator (tamoxifen or raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast cancer. The evidence for tamoxifen benefit is based on trials conducted among predominantly postmenopausal women from the general population and on studies of contralateral breast cancer in women with a pathogenic variant (mutation hereafter) in BRCA1 or BRCA2. Tamoxifen has not been assessed as a primary prevention agent in women with an inherited BRCA mutation. We conducted a prospective analysis of tamoxifen chemoprevention and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Data on tamoxifen (and raloxifene) use was collected by questionnaire and updated biennially. Information on incident cancers was collected by self-report and was confirmed by medical record review. In a matched analysis, we estimated the hazard ratio (HR) and 95% confidence intervals (CI) for developing a first primary breast cancer associated with tamoxifen or raloxifene use, using Cox proportional hazards analysis. There were 4578 unaffected women in the cohort, of whom 137 reported tamoxifen use (3%), 83 reported raloxifene use (2%) and 12 used both drugs (0.3%). Women who used tamoxifen or raloxifene were matched 1:3 with women who used neither drug on year of birth, country of residence, year of study entry and gene (BRCA1 or BRCA2). We generated 202 matched pairs. After a mean follow-up of 6.8 years, there were 22 incident breast cancers diagnosed among tamoxifen/raloxifene users (10.9% of users) and 71 cases diagnosed among non-users (14.3% of non-users; HR = 0.64; 95% CI 0.40-1.03; P = 0.07). Chemoprevention may be an effective risk-reduction option for BRCA mutation carriers, but further studies with longer follow-up are necessary.
Identifiants
pubmed: 37432545
doi: 10.1007/s10549-023-06991-3
pii: 10.1007/s10549-023-06991-3
doi:
Substances chimiques
Tamoxifen
094ZI81Y45
Raloxifene Hydrochloride
4F86W47BR6
BRCA1 protein, human
0
BRCA1 Protein
0
BRCA2 protein, human
0
BRCA2 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-264Subventions
Organisme : CIHR
ID : FDN 154275
Pays : Canada
Organisme : CIHR
ID : FDN 154275
Pays : Canada
Investigateurs
Georgia Wiesner
(G)
Aletta Poll
(A)
Raymond Kim
(R)
Jeanna McCuaig
(J)
Dana Zakalik
(D)
Fergus Couch
(F)
Linda Steele
(L)
Howard Saal
(H)
Edmond Lemire
(E)
Kim Serfas
(K)
Kevin Sweet
(K)
Seema Panchal
(S)
Christine Elser
(C)
Robert E Reilly
(RE)
Joanne L Blum
(JL)
Cezary Cybulski
(C)
Daniel Rayson
(D)
Teresa Y Cajal Ramón
(TYC)
Jeffrey Dungan
(J)
Stefania Zovato
(S)
Antonella Rastelli
(A)
Pal Moller
(P)
Stephanie Cohen
(S)
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112
doi: 10.1001/jama.2017.7112
pubmed: 28632866
Daly MB, Pal T, Berry MP et al (2021) Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(1):77–102. https://doi.org/10.6004/jnccn.2021.0001
doi: 10.6004/jnccn.2021.0001
pubmed: 33406487
Metcalfe K, Eisen A, Senter L et al (2019) International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 121(1):15–21. https://doi.org/10.1038/s41416-019-0446-1
doi: 10.1038/s41416-019-0446-1
pubmed: 30971774
pmcid: 6738089
Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7(1):46–53. https://doi.org/10.1038/nrc2048
doi: 10.1038/nrc2048
pubmed: 17186017
Force USPST, Owens DK, Davidson KW et al (2019) Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement. JAMA 322(9):857–867. https://doi.org/10.1001/jama.2019.11885
doi: 10.1001/jama.2019.11885
Gronwald J, Robidoux A, Kim-Sing C et al (2014) Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 146(2):421–427. https://doi.org/10.1007/s10549-014-3026-3
doi: 10.1007/s10549-014-3026-3
pubmed: 24951267
pmcid: 4131437
Gronwald J, Tung N, Foulkes WD et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118(9):2281–2284. https://doi.org/10.1002/ijc.21536
doi: 10.1002/ijc.21536
pubmed: 16331614
Phillips KA, Milne RL, Rookus MA et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31(25):3091–3099. https://doi.org/10.1200/JCO.2012.47.8313
doi: 10.1200/JCO.2012.47.8313
pubmed: 23918944
pmcid: 3753701
Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S (2015) Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer 22(4):327–334. https://doi.org/10.1007/s12282-015-0619-6
doi: 10.1007/s12282-015-0619-6
pubmed: 26022977
Pace LE, Keating NL (2019) Medications to reduce breast cancer risk: promise and limitations. JAMA 322(9):821–823. https://doi.org/10.1001/jama.2019.9689
doi: 10.1001/jama.2019.9689
pubmed: 31479121
Singer CF (2020) Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes. Horm Mol Biol Clin Investig. https://doi.org/10.1515/hmbci-2019-0057
doi: 10.1515/hmbci-2019-0057
pubmed: 32989958
Giannakeas V, Sopik V, Narod S (2020) A validation of methods for the evaluation of observational studies of screening mammography: an exploratory analysis based on simulating screening cohorts. Clin Epidemiol 12:1161–1169. https://doi.org/10.2147/CLEP.S267584
doi: 10.2147/CLEP.S267584
pubmed: 33149693
pmcid: 7602915
Cuzick J, Forbes J, Edwards R et al (2002) First results from the international breast cancer intervention study (IBIS-I): a randomised prevention trial. Lancet 360(9336):817–824
doi: 10.1016/S0140-6736(02)09962-2
pubmed: 12243915
Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352(9122):98–101. https://doi.org/10.1016/S0140-6736(98)85012-5
doi: 10.1016/S0140-6736(98)85012-5
pubmed: 9672274
Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371–1388
doi: 10.1093/jnci/90.18.1371
pubmed: 9747868
Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women, Italian Tamoxifen prevention study. Lancet 352(9122):93–97
doi: 10.1016/S0140-6736(98)85011-3
pubmed: 9672273
Howell A, Gandhi A, Howell S et al (2020) Long-term evaluation of women referred to a breast cancer family history clinic (Manchester UK 1987–2020). Cancers (Basel). https://doi.org/10.3390/cancers12123697
doi: 10.3390/cancers12123697
pubmed: 33317064
Macdonald C, Saunders CM, Keogh LA et al (2021) Breast cancer chemoprevention: use and views of Australian women and their clinicians. Cancer Prev Res (Phila) 14(1):131–144. https://doi.org/10.1158/1940-6207.CAPR-20-0369
doi: 10.1158/1940-6207.CAPR-20-0369
pubmed: 33115784
Metcalfe KA, Narod SA (2002) Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 94(20):1564–1569
doi: 10.1093/jnci/94.20.1564
pubmed: 12381709
King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 286(18):2251–2256
doi: 10.1001/jama.286.18.2251
pubmed: 11710890
Cuzick J, Sestak I, Bonanni B et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381(9880):1827–1834. https://doi.org/10.1016/S0140-6736(13)60140-3
doi: 10.1016/S0140-6736(13)60140-3
pubmed: 23639488
pmcid: 3671272
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M (2019) Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the us preventive services task force. JAMA 322(9):868–886. https://doi.org/10.1001/jama.2019.5780
doi: 10.1001/jama.2019.5780
pubmed: 31479143
Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ et al (2015) Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv033
doi: 10.1093/jnci/djv033
pubmed: 26264691
pmcid: 4836825
Kotsopoulos J, Huzarski T, Gronwald J et al (2017) Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw177
doi: 10.1093/jnci/djw177
pubmed: 28383664
Cancer CGoHFiB (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet Oncol 394:1159
doi: 10.1016/S0140-6736(19)31709-X
Kotsopoulos J, Gronwald J, Karlan BY et al (2018) Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.0211
doi: 10.1001/jamaoncol.2018.0211
pubmed: 29710224
pmcid: 6143051
Nolan E, Vaillant F, Branstetter D et al (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. https://doi.org/10.1038/nm.4118
doi: 10.1038/nm.4118
pubmed: 27322743
Sigl V, Owusu-Boaitey K, Joshi PA et al (2016) RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res 26(7):761–774. https://doi.org/10.1038/cr.2016.69
doi: 10.1038/cr.2016.69
pubmed: 27241552
pmcid: 5129883
Kotsopoulos J, Singer C, Narod SA (2016) Can we prevent BRCA1-associated breast cancer by RANKL inhibition? Breast Cancer Res Treat. https://doi.org/10.1007/s10549-016-4029-z
doi: 10.1007/s10549-016-4029-z
pubmed: 27798748
Oden L, Akbari M, Zaman T et al (2016) Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Oncotarget 7(52):86687–86694. https://doi.org/10.18632/oncotarget.13417
doi: 10.18632/oncotarget.13417
pubmed: 27893411
pmcid: 5349945
Widschwendter M, Burnell M, Fraser L et al (2015) Osteoprotegerin (OPG), the endogenous inhibitor of receptor activator of NF-kappaB ligand (RANKL), is dysregulated in BRCA mutation carriers. EBioMedicine 2(10):1331–1339. https://doi.org/10.1016/j.ebiom.2015.08.037
doi: 10.1016/j.ebiom.2015.08.037
pubmed: 26629528
pmcid: 4634624
Widschwendter M, Rosenthal AN, Philpott S et al (2013) The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol 14(12):1226–1232. https://doi.org/10.1016/S1470-2045(13)70448-0
doi: 10.1016/S1470-2045(13)70448-0
pubmed: 24140203
Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433–443. https://doi.org/10.1016/S0140-6736(15)60995-3
doi: 10.1016/S0140-6736(15)60995-3
pubmed: 26040499
Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. https://doi.org/10.1200/JCO.2010.29.7101
doi: 10.1200/JCO.2010.29.7101
pubmed: 21060033
Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66(12):1139–1146. https://doi.org/10.1111/ijcp.12022
doi: 10.1111/ijcp.12022
pubmed: 22967310